To order Therapeutic Apheresis Services: 877-429-4472

Therapeutic Apheresis
Therapeutic Apheresis (TA) applies apheresis technology to the clinical treatment of autoimmune diseases and blood disorders by removing selected, abnormal components or cells and returning all others. HemaCare/Coral Blood Services is the leading provider of TA in the United States, and has provided such services for over 25 years.

TA services are delivered through the use of mobile units operated at the patient's bedside or in an outpatient setting. Treatments are administered by experienced hemapheresis-trained staff under the supervision of specially trained physicians. The Company has performed over 50,000 therapeutic apheresis procedures -- more than any single organization in the world.

Therapeutic Apheresis FAQs

Sample Physician Order Forms

Clinical Application

TA provides a rapid clinical response, reduces patient complications, minimizes hospital stays and reduces overall costs of medical care for many diseases. Major clinical indications for TA include:

• Plasmapheresis
• Cytapheresis (Cell depletion)
• Leukapheresis
• Plateletpheresis
• LDL cholesterol adsorption
• Erthrocytapheresis (Red Cell Exchange)
• Stem cell harvesting
• Photopheresis

• Peripheral blood stem cell collections
• Leukapheresis
• Plateletpheresis
• Blood sample collections
• Disease state human biological products
• Therapeutic exchange plasma

Regulatory Compliance

TA services are delivered by a staff with extensive training in therapeutic apheresis. Under the direction of medical directors, the HemaCare/Coral Blood Services Quality Assurance Program is based upon guidelines developed by the American Society for Apheresis and the American Association of Blood Banks.

Compliance is assured with the broad-ranging clinical and technical standards, as defined by multiple agencies, including:

• Food and Drug Administration (FDA)
• American Association of Blood Banks (AABB)
• Joint Commission for the Accreditation of Healthcare Organizations (JCAHO)
• College of American Pathologists (CAP)
• International Society for Hematotherapy and Graft Engineering (ISHAGE)
• Foundation for the Accreditation of Hematopoietic Cell Therapy (FAHCT)
• Applicable State Departments of Health

• Melanie Osby, M.D., National Medical Director
• David Ciavarella, M.D., Regional Medical Director, Mid-Atlantic Region
• Jacquelyn Hedlund, M.D., Regional Medical Director, New England Region